Short Interest in Centogene (NASDAQ:CNTG) Decreases By 30.5%

Centogene (NASDAQ:CNTGGet Rating) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 31,700 shares, a decrease of 30.5% from the April 15th total of 45,600 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average daily volume of 12,100 shares, the days-to-cover ratio is presently 2.6 days.

NASDAQ:CNTG remained flat at $$3.37 during trading hours on Tuesday. The company’s stock had a trading volume of 171 shares, compared to its average volume of 7,699. The company has a 50-day moving average price of $3.78 and a 200-day moving average price of $5.04. Centogene has a 1 year low of $3.04 and a 1 year high of $11.95.

Centogene (NASDAQ:CNTGGet Rating) last released its quarterly earnings data on Thursday, March 31st. The company reported ($0.58) earnings per share (EPS) for the quarter. Centogene had a negative return on equity of 98.72% and a negative net margin of 24.23%. The business had revenue of $49.06 million during the quarter. Sell-side analysts anticipate that Centogene will post -1.9 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC increased its position in shares of Centogene by 10.1% in the third quarter. Millennium Management LLC now owns 498,188 shares of the company’s stock valued at $5,485,000 after buying an additional 45,655 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Centogene by 68.0% in the fourth quarter. Wells Fargo & Company MN now owns 182,728 shares of the company’s stock valued at $955,000 after buying an additional 73,984 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Centogene by 16.2% in the fourth quarter. Acadian Asset Management LLC now owns 70,725 shares of the company’s stock valued at $366,000 after buying an additional 9,854 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Centogene in the second quarter valued at $250,000. Finally, Morgan Stanley boosted its stake in shares of Centogene by 213.8% during the second quarter. Morgan Stanley now owns 18,662 shares of the company’s stock valued at $194,000 after acquiring an additional 12,715 shares during the last quarter.

Separately, Zacks Investment Research upgraded Centogene from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 25th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $18.75.

Centogene Company Profile (Get Rating)

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.

Featured Articles

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.